empagliflozin / Linagliptin

Known as: EMPAGLIFLOZIN/LINAGLIPTIN, linagliptin and empagliflozin 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
02420152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AIMS This double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov NCT02453555) evaluated the efficacy and safety… (More)
Is this relevant?
2018
2018
INTRODUCTION Two 52-week Phase III studies evaluated the efficacy and safety of once-daily combinations of empagliflozin… (More)
Is this relevant?
Review
2017
Review
2017
INTRODUCTION Type 2 diabetes mellitus (T2DM) is typically progressive, with sequential addition of therapies often needed to… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2017
Review
2017
Type 2 diabetes (T2D) generally requires a combination of several pharmacological approaches to control hyperglycaemia. Combining… (More)
Is this relevant?
Review
2016
Review
2016
INTRODUCTION The duration of uncontrolled type 2 diabetes mellitus (T2DM) can adversely impact small and large vessels… (More)
  • table 1
  • figure 1
Is this relevant?
Review
2016
Review
2016
Glyxambi® (empagliflozin/linagliptin) is a fixed-dose, once-daily tablet combining a sodium glucose co-transporter-2 (SGLT2… (More)
Is this relevant?
2016
2016
BACKGROUND Sodium-glucose co-transporter-2 (SGLT2) inhibitors are new oral antidiabetic drugs that reduce hyperglycemia by… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2016
Review
2016
INTRODUCTION Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require a combination of several… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
OBJECTIVE To evaluate the efficacy and safety of combinations of empagliflozin/linagliptin as second-line therapy in subjects… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2015
2015
OBJECTIVE To evaluate the efficacy and safety of empagliflozin/linagliptin in subjects with type 2 diabetes. RESEARCH DESIGN… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?